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ABSTRACT 
The HPTLC method is based on separation of the two drugs followed by the 
densitometric measurements of their spots at 277 nm. The separation was 
carried out on Silica gel 60GF254 using mobile phase Ethylacetate: Methanol: 
Chloroform: Glacial acetic acid (60:20:19:1 v/v/v/v). The linearity range lies 
between 250-1500 ng/spot for Sumatriptan Succinate and 1000-6000 ng/spot 
for Naproxen Sodium with correlation coefficients of 0.997 and 0.996 
respectively. The Rf value for Sumatriptan Succinate is 0.49±0.02 and for 
Naproxen Sodium is 0.28±0.02%. Recoveries of Sumatriptan Succinate and 
Naproxen Sodium was in the range of 99.54-100.50% and 99.75-100.07% 
respectively. LOD value for Sumatriptan Succinate was 39.85 ng/spot and for 
Naproxen Sodium was 80.35 ng/spot. LOQ value for Sumatriptan Succinate was 
120.77 ng/spot and for Naproxen Sodium was 243.5 ng/spot. The developed 
method was validated as per ICH Guidelines. 
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INTRODUCTION
Sumatriptan Succinate[1-5] is a synthetic 
drug belonging to the triptan class and 1-[3-(2-
dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-
methanesulfonamide. Selective 5-
hydroxytryptamine1 (5-HT1) receptor subtype 
agonist act as antimigraine. Naproxen Sodium[1-
5] is a nonsteroidal anti-inflammatory drug 
(NSAID) and (2S)-2-(6-methoxynaphthalen-2-
yl) propanoic acid. It is arylacetic acid group act 
as pain relief than used as antimigraine. Most of 
antimigraine drugs are not available in 
combined dosage form.  
Spectroscopical method and 
chromatographical method like HPLC, HPTLC[6-
8] are considered to be most suitable for the 
simultaneous estimation of drug present in a 
multi component dosage form. 
The present paper describes a simple, 
accurate and precise method for simultaneous 
estimation of Sumatriptan Succinate and 
Naproxen Sodium in combined pharmaceutical 
dosage form. HPTLC method for Sumatriptan 
Succinate is published[9]. Some article on HPLC 
for Sumatriptan Succinate[10-12] and Naproxen 
Sodium[13,14] were published. 
The proposed method is optimized and 
validated as per the International Conference on 
Harmonization (ICH) guidelines[15]. 
 
Figure 1: Sumatriptan Succinate 
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Figure 2: Naproxen Sodium 
MATERIALS AND METHODS  
Chemicals and reagents  
Sumatriptan Succinate and Naproxen 
Sodium working standards were procured from 
Sun Pharmaceutical and Divi’s Laboratory 
respectively, and the tested pharmaceutical 
formulations (Headset Sumatriptan Succinate 
(119mg) and Naproxen Sodium (500 mg) 
tablet) were procured from commercial 
pharmacy. All reagents used were of suitable 
analytical grade.  
Chromatographic Conditions  
The instrument used for the estimation 
was CamagLinomat V semi automatic sample 
applicator, Camag TLC scanner III, WinCATs 
software for interpretation of the data, 
Hamilton syringe and Camag twin trough 
chamber. The Mobile phase was Ethylacetate: 
methanol: chloroform: Glacial acetic acid 
(60:20:19:1). Chamber saturation time was 
20min. Detection was performed at 277nm. 
Preparation of Standard Solution  
250 mg of Sumatriptan Succinate and 
500 mg of Naproxen Sodiumwere dissolved and 
diluted with methanol upto 100ml. (2500μg/ml 
of Sumatriptan Succinate and 5000μg/ml of 
Naproxen Sodium).  
Preparation of Calibration curve 
The working standard stock solution 
containing the mixture in the ratio of (1:4) of 
Sumatriptan Succinate and Naproxen Sodium. 
From 250 ng/µl Sumatriptan Succinate solution 
applied 1, 2, 3, 4, 5 and 6 ng/µl to the plate for 
the calibration curve were obtained 250-1500 
ng/spot of Sumatriptan Succinate. From 1000 
ng/µl Naproxen Sodium solution applied 1, 2, 3, 
4, 5 and 6 ng/µl to the plate for the calibration 
curve were obtained 1000-6000 ng/spot of 
Naproxen Sodium. 
 
 
Preparation of Sample Solution  
20 tablets (Headset) were weighed and 
powdered. Powder equivalent to 23.8 mg of 
Sumatriptan Succinate and 100 mg of Naproxen 
Sodium transferred into 100ml volumetric flask. 
Methanol was added to adjust level up to mark 
and sonicated for 10 min. The solution was 
filtered through whatman filter paper no. 42. 
First few ml of filtrate was discarded. 1 ml of 
this solution diluted for 10ml to give 238 ng/µl 
Sumatriptan Succinate and 1000 ng/µl 
Naproxen Sodium. 1 µl of this solution is used 
for the estimation. 
RESULTS AND DISCUSSION  
The present study was aimed at 
development of speedy and cost effective 
HPTLC technique for determination of 
Sumatriptan Succinate and Naproxen Sodium in 
pharmaceutical dosage forms. 
Various blends of solvent systems in 
varying proportions were tried as mobile phase. 
However, mobile phase consisting ethyl acetate: 
methanol: chloroform: glacial acetic acid 
(60:20:19:1) was found to be more suitable 
with Rf values of 0.49±0.02 and 0.28±0.02 for 
Sumatriptan Succinate and Naproxen Sodium, 
respectively with saturation time of 20 minutes. 
The selection of wave length was based on 
maximum absorbance for optimum sensitivity. 
The drugs showed good linearity in the range of 
250-1500 ng/spot for Sumatriptan Succinate 
and 1000-6000 ng/spot for Naproxen Sodium 
with coefficient of correlation value 0.997 and 
0.996, respectively. From the recovery studies, 
the accuracy results were 99.54-100.50% for 
Sumatriptan Succinate and 99.75-100.07%for 
Naproxen Sodium and were found to be highly 
accurate. 
Validation of the Method 
1. Linearity and Range: Linearity was found in 
the range of 250-1500 ng/spot for Sumatriptan 
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Succinate and 1000-6000 ng/spot for Naproxen 
Sodium. The drug peak area was calculated for 
each concentration level and a graph was 
plotted of drug concentration against the peak 
area. 
Table 1: Calibration parameters 
Parameters  SUM NAP 
Linearity range (ng/spot)  250-1500  1000-6000  
Linearity equation  y = 5.962x + 3683 y = 0.767x + 1244 
Co-relation coefficient  0.997 0.996  
Slope  5.962  0.767  
Intercept  3683  1244 
 
 
Figure 3: Chromatogram of mixed standard solution containing 250 ng/spot of Sumatriptan 
Succinate and 1000 ng/spot of Naproxen Sodium 
 
Figure 4: 3D view of all tracks of Sumatriptan Succinate and Naproxen Sodium 
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2. Precision: The precision expressed as 
standard deviation or relative standard 
deviation. Combined dosage form was analyzed 
at three levels of concentration of the assay for 
three times in a day. Peak Area of the solutions 
was measured. 
2.1 The data for Repeatability % R.S.D. was 
found to be 0.2209% for Sumatriptan 
Succinate and 0.2911% for Naproxen 
Sodium. 
2.2 The data for intraday % R.S.D. was found to 
be 0.5099% for Sumatriptan Succinate and 
0.6960% for Naproxen Sodium. 
2.3 The data for interday % R.S.D was found to 
be 0.5661% for Sumatriptan Succinate and 
0.8989% for Naproxen Sodium.  
3. Specificity: Specificity is carried out by taking 
peak purity of standard and sample of each drug 
and standard and sample peak spectra were 
overlain to check specificity of each individual 
drug peak.  
 
Figure 5: Peak purity graph of Sumatriptan Succinate and Naproxen Sodium 
Table 2: Specificity data 
Drug  Co-relation r (s,m)  Co-relation r (m,e)  Peak purity  
SUM  0.999564  0.998809  Pass  
NAP 0.999 490 0.998730 Pass  
4. Accuracy (Recovery study): The accuracy of 
the method was established using recovery 
technique i.e external standard addition 
method. The known amount of standard was 
added at three different levels to preanalysed 
sample. Each determination was performed in 
triplicate.  
Table 3: Accuracy Results 
Sr. 
No. 
Assay 
level 
Tablet content 
taken(ng/spot) 
Standard 
added 
(ng/spot) 
Total drug 
recovered 
(ng/spot) 
% Recovery ±S.D 
 (n=3) 
SUM NAP SUM NAP SUM NAP SUM NAP 
1  500 2000 - - 499.23 2000.4 - - 
2 80% 500 2000 250 1000 750.98 3001.6 100.50±0.46 100.17±0.5 
3 100% 500 2000 500 2000 1000.9 4000.7 100.25±0.25 100.04±0.4 
4 120% 500 2000 750 3000 1250.4 4999.7 100.1±0.23 99.99±0.25 
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Table 4: Assay result of marketed formulation by HPTLC method 
Formulation Tablet content taken 
eq. to (ng/spot) 
Amount found 
(ng/spot) 
Assay (%estimated) 
(n±3) 
Headset (Label claim 
SUM=119 mg & 
NAP=500 mg) 
SUM  NAP SUM  NAP SUM  NAP 
119 500 118.20 501.49 99.32±0.56 100.3±0.92 
5. LOD 
LOD was found to be 39.85 ng/spot for 
Sumatriptan Succinate and 80.35 ng/spot for 
Naproxen Sodium. 
6. LOQ 
LOD was found to be 120.77 ng/spot for 
Sumatriptan Succinate and 243.5 ng/spot for 
Naproxen Sodium. 
CONCLUSION 
Sumatriptan Succinate and Naproxen 
Sodium show maximum UV absorption at 277 
nm. Hence, an appropriate method of 
estimation when these drugs are administered 
together is chromatographic analysis. HPTLC 
determination of Sumatriptan Succinate and 
Naproxen Sodium shows no interference 
between two drugs and from the excipients it 
also shows the method is rapid, allowing a high 
sample throughput necessary for routine 
analysis with an added advantage of low solvent 
consumption. The method described herein is 
simple, rapid, selective method and well suited 
for quantitative estimation of Sumatriptan 
Succinate and Naproxen Sodium individually 
and from pharmaceutical preparations.  
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